Personalized Circulating tumor DNA as a Predictive Biomarker in High-Risk Early Stage Breast Cancer Treated With Neoadjuvant Chemotherapy Published Date October 14, 2022 Expand Fullscreen Exit Fullscreen Download PDF Expand Fullscreen